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Background: Persin is a plant toxin that displays synergistic cytotoxicity with tamoxifen in human breast cancer cell lines. Here, we
examined the ability of persin to circumvent tamoxifen resistance and delineated the intracellular signalling pathways involved.
Methods: The induction of apoptosis in tamoxifen-resistant and -sensitive breast cancer cells was measured by flow cytometry
following treatment with persin±tamoxifen. Markers of endoplasmic reticulum stress (ERS) were analysed following treatment,
and their causal role in mediating persin-induced apoptosis was determined using chemical inhibitors and RNA interference.
Results: Cells that were resistant to an apoptotic concentration of tamoxifen maintained an apoptotic response to persin. Persin-
induced apoptosis was associated with an increase in markers of ERS, that is, CHOP expression and XBP-1 splicing and was
decreased by CHOP siRNA. The CASP-4 inhibitor Z-YVAD-FMK markedly inhibited persin-induced apoptosis in both tamoxifen-
sensitive and -resistant cells.
Conclusion: The cytotoxic effects of persin are CASP-4 dependent and mediated by CHOP-dependent and -independent ERS
signalling cascades. Increased ERS signalling contributes to persin-induced reversal of tamoxifen resistance.
Breast cancer remains the most common cancer of women and the
second most frequent cause of cancer death despite a major decline
in breast cancer mortality in the past decade. However, despite the
widespread clinical efficacy of endocrine therapies for the
treatment of breast cancer, they are ineffective as therapy for
oestrogen receptor (ER)-negative disease, and even among those
patients with ER-positive disease that do initially respond, intrinsic
or acquired therapeutic resistance remains a major obstacle to an
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effective cure (reviewed in Musgrove and Sutherland, 2009). Thus,
there is a clear need for the development of novel therapeutic
strategies that can enhance and broaden responsiveness, particu-
larly in hormone refractory disease.
There is now accumulating evidence that aberrant apoptosis
regulation has an important role in the development of endocrine
resistance (Butt et al, 2007; Musgrove and Sutherland, 2009). More
specifically, recent studies have highlighted the role of the
endoplasmic reticulum in the initiation of a pathologically and
therapeutically relevant apoptotic programme (Moenner et al,
2007; Liao et al, 2008) which, when disrupted, can be associated
with anti-oestrogen resistance (Gomez et al, 2007). Imbalances in
endoplasmic reticulum homeostasis triggered through cellular
stresses such as hypoxia, low glucose or through the accumulation
of misfolded proteins leads to the generation of an endoplasmic
reticulum-mediated stress response and the triggering of an
intrinsic apoptotic pathway, mediated, in part, through the
generation of ceramide (Liao et al, 2008).
The endoplasmic reticulum stress (ERS) response has also been
a recent focus from a cancer therapeutic perspective, given its
emerging role as a protective mechanism against chemotherapy-
induced cytotoxicity and as a potential initiating step in the
development of chemoresistance (reviewed in Scho¨nthal, 2009).
Cancer cells often display elevated levels of ERS markers compared
with their non-malignant counterparts, leading to the hypothesis
that they exist in a state of chronic, low level ERS as an adaptive
mechanism to enable growth and survival under adverse condi-
tions, such as hypoxia and low nutrient environments. This
differential ERS status of normal and malignant cells also provides
an opportunity for therapeutic intervention as it may sensitise
cancer cells to inducers of apoptosis.
Phytochemicals have provided a particularly abundant source of
anti-cancer agents (Nishino et al, 2005), and we have previously
described a novel plant toxin, persin, that has unique, in vivo
actions in the mammary epithelium and potent apoptotic effects in
human breast cancer cells in vitro (Butt et al, 2006). Persin is an
avocado acetogenin, derived from the biosynthesis of long-chain
fatty acids with close structural homology to the essential n-6
polyunsaturated fatty acid (PUFA), linoleic acid. Interestingly,
conjugated linoleic acids (linoleic acid isomers) have anti-
carcinogenic properties with particular efficacy against breast
cancer (Ip et al, 2002). Furthermore, other PUFAs structurally
similar to persin can attenuate steroid hormone receptor sensitivity
to circulating oestrogens by direct modulation of receptor levels,
and these data have formed the rationale for a promising phase II
clinical trial of gamma linoleic acid and the anti-oestrogen,
tamoxifen as primary therapy for breast cancer, which demon-
strated a significant improvement in the overall clinical response
(Kenny et al, 2000). Persin also exhibits potent synergistic
cytotoxicity with the active metabolite of tamoxifen, 4-hydro-
xytamoxifen (4-OHT) in vitro in both ER-positive and ER-negative
breast cancer cells, but not in phenotypically normal, breast
epithelial cells (Roberts et al, 2007). This synergy is mediated via
enhanced ceramide signalling—more specifically, persin generates
de novo ceramide production that is further enhanced by 4-OHT’s
inhibition of ceramide glycosylation (Roberts et al, 2007). Thus, the
generation of an ERS response mediated by ceramide signalling
could represent an upstream initiating event in persin-induced
cytotoxicity, which could, in turn, impact on its ability to modulate
tamoxifen responsiveness.
Herein, we have further defined the mechanistic basis of persin-
induced cytotoxicity and synergy with 4-OHT in human breast
cancer cells, by determining its effects on ERS pathways in 4-OHT-
sensitive and -resistant cell lines. We demonstrate that persin
causes apoptosis in both 4-OHT-sensitive and -resistant cell lines.
Persin treatment results in a robust ERS response with evidence
that persin’s ability to augment the pro-apoptotic response to
4-OHT is mediated through enhanced ERS signalling. These data
not only define the intracellular pathways mediating persin’s
actions in breast cancer cells, but also highlight potential
therapeutic strategies through which 4-OHT resistance may be
overcome.
MATERIALS AND METHODS
Purification and isolation of persin. The isolation and purifica-
tion of persin from milled freeze-dried leaves of the avocado,
P. americana, and monitoring of batch purity has previously been
described (Oelrichs et al, 1995).
Cell lines and reagents. The human breast cancer cell lines
MCF-7 (Michigan Cancer Foundation, Detroit, MI) and T-47D (EG&G
Mason Research Institute, Worcester, MA, USA) were maintained
in RPMI-1640 medium supplemented with 5% fetal calf serum
(FCS), 10 mgml 1 insulin, and 2mM glutamine under standard
conditions. The TAM-R cell line was derived from MCF-7 cells as
previously reported (Knowlden et al, 2003) and was maintained in
phenol red-free RPMI-1640 supplemented with 5% charcoal-
stripped-steroid-depleted FCS, 4mM glutamine, and 100 nM
4-OHT. MCF 5-21 (4-OHT sensitive) and MCF 5-23 (4-OHT
resistant) sub-clones of MCF-7 cells (Hu et al, 1993) were
maintained in 10% FCS, 10 mgml 1 insulin, and 4mM glutamine.
4-OHT was purchased from Sigma (St Louis, MO, USA), CASP-4
inhibitor, Z-YVAD-FMK and pan-caspase inhibitor, Z-VAD-FMK
were purchased from R&D Systems (Minneapolis, MN, USA), and
tunicamycin was purchased from Merck Pty. Ltd. (Kilsyth, VIC,
Australia).
Measurement of apoptosis by flow cytometry. For M30 analysis,
floating and attached cell populations were combined, fixed, and
permeabilised in ice-cold methanol and then resuspended in PBS/
0.5% bovine serum albumin with FITC-conjugated M30 Cyto-
DEATH monoclonal antibody (Enzo Life Sciences, Farmingdale,
NY, USA) before the M30-positive (apoptotic) population was
determined by flow cytometry on BD FACSCantoII (Becton
Dickinson, Mountain View, CA, USA).
Immunoblot analysis. Proteins from whole-cell lysates were
resolved under reducing conditions on 12% SDS-polyacrylamide
gels using standard methods. Resolved proteins were transferred
onto polyvinylidene difluoride membranes and probed with
antibodies against binding immunoglobulin protein (BiP) (Cell
Signaling Technology, Danvers, MA, USA), CCAAT/enhancer
binding protein homologous transcription factor/growth arrest and
DNA damage-inducible gene 153 (CHOP/GADD153) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), Bim (Calbiochem,
Darmstadt, Germany) and ERa (Santa Cruz Biotechnology)
overnight at 4 1C. Immunoreactive protein bands were detected
by the relevant anti-IgG antibodies conjugated with horseradish
peroxidase followed by enhanced chemiluminescence (Pierce,
Rockford, IL, USA). Blots were checked for equal loading by
reprobing with anti-b-actin antibody (Sigma).
XBP-1 activation assay. Cells were incubated for 8, 16, or 24 h
with tunicamycin, persin, or vehicle control, total RNA was
isolated using the RNeasy kit (Qiagen, Limberg, The Netherlands)
and 1mg was reverse transcribed using the Reverse Transcription
System (Promega, Madison, WI, USA) according to the manu-
facturer’s instructions. XBP-1 cDNA was amplified using human-
specific primers (GeneWorks; forward: 50-AAACAGAGTAGCA
GCTCAGACTGC-30; reverse: 50-GTATCTCTAAGACTAGGG
GCTTGGTA-30) and Pfu DNA Polymerase (Promega), and the
PCR product digested with PstI restriction enzyme (Promega) for
6 h. The digested PCR product was then separated using 2%
agarose gel electrophoresis.
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Caspase-4 inhibition. Cells were incubated for 24 h with persin,
persin and the CASP-4-specific inhibitor Z-YVAD-FMK (20 mM),
persin and the pan-caspase inhibitor Z-VAD-FMK (20 mM) or
vehicle control. M30 analysis was used to determine apoptosis.
RNA interference. Small interfering RNA (siRNA) specific for
CHOP (ON-TARGETplus SMART pool human DDIT3) and non-
targeting controls (ON-TARGETplus siCONTROL) was purchased
from Dharmacon Inc. (Lafayette, CO, USA). At seeding, cells were
transfected with Lipofectamine 2000 (Invitrogen Life Technology
Inc., Carlsbad, CA, USA) in the presence of siRNAs according to
the manufacturer’s protocol. Following overnight incubation, cells
were treated with persin and/or 4-OHT for a further 24 h.
Statistical analysis. All data represent the mean of at least three
independent experiments. Statistical analysis was carried out using
GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA,
USA). Differences between groups (control and treated) were
evaluated by two-tailed, unpaired Student’s t-test, or one-way
ANOVA with Tukeys multiple comparison test (synergy analysis),
and a P-value ofo0.05 was considered as statistically significant.
RESULTS
Response of TAM-R cells to persin. The two resistance models
used in this study are the TAM-R acquired resistance model
developed through continuous passage of MCF-7 cells for 6
months in the presence of 4-OHT (Knowlden et al, 2003), and a
de novo resistance model consisting of 4-OHT-sensitive (MCF
5-21) and 4-OHT-resistant (MCF 5-23) sub-clones of MCF-7
derived by limiting dilution (Hu et al, 1993). It has previously been
demonstrated that TAM-R and MCF 5-23 cells are resistant to
cytostatic concentrations of 4-OHT, that is, o1 mM (Knowlden
et al, 2003). Here, we have further characterised these models and
shown that they are also resistant to an apoptotic concentration of
4-OHT (7.5 mM; Figure 1A) compared with their sensitive
counterparts (Figure 1A).
Having demonstrated a differential apoptotic response to
4-OHT, we determined whether resistant cells exhibited a broader
apoptotic resistance by determining their response to an apoptotic
concentration of persin. Figure 1B shows that in both of the cell
models there was a significant increase in apoptosis (as determined
by M30 positivity) following persin (10 mgml 1) treatment,
regardless of the sensitivity of the cells to 4-OHT suggesting that
intact apoptotic pathways are maintained despite the development
of 4-OHT resistance. However, while both TAM-R and MCF 5-21/23
cells displayed a similar differential response to 4-OHT
(Figure 1A), the TAM-R cell model displayed a more pronounced
apoptotic response to persin than the MCF 5-21/23 model
(Figure 1B).
Co-treatment with persin reverses 4-OHT resistance in TAM-R
and MCF 5-23 cells. Our previous studies have demonstrated a
cytotoxic synergy between persin and 4-OHT in human breast
cancer cells (Roberts et al, 2007). We determined the effects of a
lower, non-apoptotic concentration of persin on the apoptotic
response to 4-OHT in both the 4-OHT resistant cell lines, TAM-R
and MCF 5-23. Following treatment with persin (1 mgml 1) and
4-OHT (7.5 mM) alone or in combination for 24 h, apoptosis was
determined by flow cytometric analysis of cells stained using
the M30 CytoDEATH antibody. Figure 2A is an overlay of
representative histograms, showing a robust induction of apoptosis
in cells receiving the combined treatment. The graphs in Figure 2B
show data combined from at least three independent experiments
and demonstrate the significantly augmented apoptotic response
when persin was used in combination with 4-OHT compared with
either single agent alone—an effect that was observed in both of the
4-OHT-resistant cell lines examined.
Persin-induced apoptosis is associated with an increase in
markers of ERS. To further explore the mechanistic basis of
persin-induced cytotoxicity, we examined components of ERS
signalling pathways in two persin-sensitive human breast cancer
cell lines, MCF-7 and T-47D, using the known ERS inducer,
tunicamycin, as a positive control. Our previous studies have
demonstrated a robust induction of apoptosis in both MCF-7 and
T-47D cells following 24 h treatment with persin (Butt et al, 2006;
Roberts et al, 2007). Here, we examined the effects of an apoptotic
concentration of persin (10 mgml 1) or tunicamycin (10 mgml 1)
on several markers of the ERS response—expression of
BiP, CHOP/GADD153 (C/EBP homologous protein/DNA
damage-inducible gene 153) and splicing of X-box-binding
protein-1 (XBP-1).
Figure 3A demonstrates that treatment of breast cancer cells
with persin (10 mgml 1) results in an induction of BiP and CHOP
to levels comparable to the known ERS inducer, tunicamycin.
Persin treatment resulted in a significant induction of CHOP
within 16 h and BiP by 24 h in both cell lines (Figure 3A).
Splicing of XBP-1 mRNA is stimulated by ERS as part of the
unfolded protein response (UPR). XBP-1 isoforms were identified
and quantitated in breast cancer cells treated with persin
(10 mgml 1), tunicamycin (10 mgml 1), or vehicle control
(Figure 3B). Figure 3C demonstrates that splicing of XBP-1 in
persin-treated cells followed a similar activation profile to CHOP
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Figure 1. The response of 4-OHT-sensitive and -resistant breast
cancer cells to both tamoxifen and persin-induced apoptosis. (A) MCF-
7/TAM-R and MCF 5-21/23 cells were treated with an apoptotic
concentration of 4-OHT (7.5mM) or vehicle control, and the induction of
apoptosis was analysed in attached and floating cells by M30-FITC
positivity 24 h after treatment. Values are calculated from at least three
independent experiments±s.e. (B) MCF-7/TAM-R and MCF 5-21/23
cells were treated with an apoptotic concentration of persin
(10 mgml 1) or vehicle control, and the induction of apoptosis was
analysed in attached and floating cells 24 h after treatment. Values are
calculated from at least three independent experiments±s.e.
**Po0.005, ***Po0.001, ****Po0.0001 for treated cells vs untreated
controls.
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Figure 2. Co-treatment with persin and 4-OHT reverses 4-OHT resistance. (A) TAM-R and MCF 5-23 cells were treated with a non-apoptotic
concentration of persin (1mgml 1) or 4-OHT (7.5mM) alone or in combination for 24 h, then attached and floating populations were analysed for
M30-FITC positivity by flow cytometry. Overlays of representative histograms showing the M30-FITC-positive (apoptotic) fraction. (B) Bars, mean of
M30-positive fractions from at least three independent experiments±s.e. **Po0.01, ***Po0.001, for combination treatment vs single treatment.
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Figure 3. Persin-induced apoptosis is associated with the upregulation and activation of markers of endoplasmic reticulum stress. (A) MCF-7 and
T-47D cells were treated with an apoptotic concentration of persin (P; 10mgml 1), the endoplasmic reticulum stress inducer, tunicamycin
(T; 10mgml 1), or untreated (C) for 8, 16, or 24 h, and levels of BiP and CHOP were determined by immunoblotting. b-Actin was used as a loading
control. Representative blots from three independent experiments are shown. (B) MCF-7 and T-47D cells were treated with tunicamycin
(T; 10mgml 1), an apoptotic concentration of persin (P; 10mgml1) or vehicle control (C) for 8, 16, or 24 h. RNA was then collected, cDNA
produced, XBP-1 cDNA amplified using PCR, and the product digested with the restriction enzyme PstI to determine the proportion of undigested
(active) to digested (inactive) XBP-1. Representative gels from at least three independent experiments are shown. (C) Densitometric analysis of
undigested vs digested XBP-1 PCR product in MCF-7 and T-47D cells treated with tunicamycin (10mgml 1) or persin (10mgml1) for 8, 16,
or 24 h, and vehicle controls. Bars, mean of three independent experiments±s.e. *Po0.05 for treated cells vs untreated controls.
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induction—XBP-1 was significantly activated within 16 h of
treatment and activation was sustained for up to 24 h. Tunicamy-
cin activated XBP-1 within 8 h in both cell lines.
Interestingly, differential temporal dynamics were observed in
the ERS response to persin compared with tunicamycin. Treatment
with the latter initiated a more rapid response (within 8 h) from all
ERS markers examined compared with persin, but the response to
persin was more sustained, typically being maintained up to 24 h
following treatment.
The role of ERS in persin-induced apoptosis. Having identified
an increase in markers of ERS associated with persin treatment,
we then determined the role of the ERS response in the induction
of persin-induced apoptosis. Since CHOP induction is central to
ERS response pathways (Kim et al, 2008), we examined the effects
of attenuating CHOP expression using specific siRNA. The
induction of CHOP protein expression following 24 h treatment
with an apoptotic concentration of persin (10 mgml 1) was
typically reduced by B85% in the presence of CHOP siRNAs
(Figure 4A). Figure 4B shows that this attenuation of CHOP
expression significantly decreased persin-induced apoptosis in
MCF-7 cells.
As CASP-4 has a role in mediating ERS-induced apoptosis (Kim
et al, 2008), we next examined the role of CASP-4 activation in the
apoptotic response to persin in MCF-7 and T-47D cells using the
CASP-4-specific inhibitor, Z-YVAD-FMK. Cells were treated with
an apoptotic concentration of persin (10 mgml 1) in the presence
or absence of Z-YVAD-FMK (20 mM) or the pan-caspase inhibitor,
Z-VAD-FMK (20 mM) and apoptosis determined by M30-cyto-
DEATH antibody staining. Figure 5A shows representative
histograms of apoptosis induction in both cell lines following
single agent or combined treatment. Combined data from three
independent experiments demonstrate a significant attenuation of
persin-induced apoptosis in both cell lines following treatment
with Z-YVAD-FMK at comparable levels to broad spectrum
caspase inhibition (Figure 5B), suggesting that it is predominantly
mediated through a CASP-4-dependent, ERS signalling cascade.
Collectively, these results suggest that persin’s apoptotic effects
in breast cancer cells are mediated predominantly via CHOP-
dependent ERS signalling cascades that induce apoptosis through
CASP-4 activation.
Persin-induced apoptosis in 4-OHT-resistant cells is associated
with markers of ERS. When 4-OHT-resistant cells were treated
with an apoptotic concentration of persin (10 mgml 1), they
showed changes in ERS markers similar to the 4-OHT-sensitive
MCF-7 and T-47D cells: treatment of TAM-R and MCF 5-23 cells
with persin (10 mgml 1) for 24 h resulted in an increase in CHOP
expression (Figure 6A). Interestingly, we also observed a decrease
in ERa expression in 4-OHT-resistant cells in response to persin
(Figure 6A) as previously observed in persin-sensitive cells
(Roberts et al, 2007). These effects on the ERS response appear
to be specific for persin, as treatment of TAM-sensitive cells with
apoptotic concentrations of 4-OHT did not result in any changes
in CHOP expression compared with untreated controls
(Figure 6B).
Persin and 4-OHT proapoptotic synergy is mediated via an ERS
response. We then proceeded to determine what role persin-
induced ERS played in persin’s ability to reverse 4-OHT resistance.
When the 4-OHT-resistant cell lines TAM-R and MCF 5-23 were
treated with a low non-apoptotic concentration of persin
(1 mgml 1) and an apoptotic concentration of 4-OHT (7.5mM),
CHOP protein expression was increased (Figure 6C), and again,
a significant decrease in ERa was also observed. These changes are
greater than the additive effect of the single agents alone.
We further delineated the molecular mechanisms driving the
proapoptotic synergy between persin and 4-OHT by determining
the cellular effects of inhibiting CASP-4 on the observed synergistic
response. Figure 6D shows that treatment with the CASP-4
inhibitor significantly abrogated persin and 4-OHT-induced
apoptosis. In TAM-R cells, apoptosis was reduced to levels
observed in vehicle-treated control cells, whereas in MCF 5-23
cells, the apoptosis was reduced by B50%.
DISCUSSION
As the mechanisms of mammalian cell death signalling become
further delineated, the possibility of manipulating the intracellular
apoptotic machinery for therapeutic benefit is being explored
experimentally (Liu et al, 2011), with several apoptosis-inducing
therapies showing early promise in the clinical trial setting (Reed,
2002). From a breast cancer perspective, while the role of apoptosis
in influencing the endocrine response is still evolving (Butt et al,
2007; Musgrove and Sutherland, 2009), the possibility of com-
bining endocrine therapies with those inducing apoptosis has
significant potential to both maximise responsiveness and
circumvent resistance. However, such advances are dependent
upon a deeper understanding of the molecular determinants of
4-OHT responsiveness and the intracellular apoptotic signalling
cascades that impinge upon them.
In our previous preclinical studies, we described the cytostatic
and cytotoxic efficacy of the avocado-derived toxin, persin in
human breast cancer cell lines (Butt et al, 2006), as well as
demonstrating its ability to sensitise both ER-negative and ER-
positive cells to the apoptotic effects of 4-OHT through
modulations of de novo sphingolipid biosynthesis (Roberts et al,
2007). Given this ability to modulate the sensitivity to 4-OHT, we
have extended our previous work to further dissect the interactions
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Figure 4. The role of CHOP in the induction of persin-induced
apoptosis. (A) MCF-7 cells were treated for 24 h with CHOP-specific
siRNAs (siCHOP; 20 nM), non-targeting controls (siNT; 20 nM) or mock
transfected and then treated for a further 24 h with an apoptotic
concentration of persin (P; 10mgml 1) or vehicle control (C). Protein
samples were prepared and analysed for CHOP expression by
immunoblotting. Representative blots from four independent
experiments are shown. b-Actin was used as a loading control.
(B) Attached and floating populations were then analysed for M30-FITC
positivity by flow cytometry. Bars, mean of M30-positive fractions from
four independent experiments±s.e. **Po0.005 for CHOP siRNA
treatment vs NT siRNA treatment.
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between persin-induced apoptosis and the cellular response to
4-OHT, thereby gaining greater insight into the pathways
governing anti-oestrogen resistance.
This study demonstrates that while tamoxifen-resistant cells are
resistant to an apoptotic concentration of 4-OHT, they retain a
robust apoptotic response to persin—comparable to that observed
in their 4-OHT-sensitive counterparts. This suggests that the block
to 4-OHT-induced cell death in these cell models may occur either
upstream in the apoptotic cascade relative to persin action, or via a
parallel pathway. The former hypothesis is further supported by
the ability of persin to circumvent 4-OHT resistance and restore
sensitivity to 4-OHT-induced apoptosis.
These data provided the rationale for further exploration of the
mechanistic basis of persin-induced cytotoxicity and its point
of convergence with 4-OHT-mediated apoptotic signalling.
Previously, we have shown that Bim, c-Jun NH2-terminal kinase
(JNK), and ceramide are all upstream mediators of persin-induced
apoptosis (Butt et al, 2006; Roberts et al, 2007). As all of these have
been implicated in ERS pathways (Woodcock, 2006; Puthalakath
et al, 2007), we further explored the effects of persin on the cellular
ERS response.
We showed that persin elicits a robust ERS response in MCF-7
and T-47D breast cancer cells as determined by the induction/
activation of ERS markers, BiP, CHOP, and XBP-1, to levels
comparable to those following treatment with the known ERS
inducer, tunicamycin. Furthermore, this increase in ERS signalling
appears to be causal, at least in part, for persin-induced apoptosis
as demonstrated by inhibition of CHOP and CASP-4—central
mediators of the ERS response. However, persin-induced apoptosis
was not completely ameliorated by knockdown of CHOP
expression with siRNA, suggesting either some remaining func-
tional CHOP expression following siRNA treatment, or that
CHOP-independent pathways may also be involved in mediating
persin’s cytotoxicity.
CHOP induction is the point of convergence for three
upstream ERS transducers localised on the endoplasmic
reticulum membrane—PKR-like endoplasmic reticulum kinase
(PERK), activating transcription factor 6 (ATF6), and Ire1. These
transducers are activated under ERS conditions when the unfolded
protein sensor, BiP dissociates from them to bind to unfolded
proteins in the endoplasmic reticulum (Oyadomari and Mori, 2004).
CASP-4 is localised to the endoplasmic reticulum membrane and
there are now several lines of evidence pointing to its central role as
a mediator of ERS-induced apoptosis in cancer cells (Hitomi et al,
2004; Kim et al, 2008), including the abrogation of ERS-mediated
apoptosis by CASP-4 inhibition in several cancer cell models
(reviewed by Di Fazio et al, 2012).
Persin’s effects on BiP suggest that it may act upstream of the
ERS cascade, but whether this is via a direct interaction with BiP or
indirectly through alternate intermediaries remains not yet clear.
However, since de novo ceramide synthesis takes place in the ER,
there may be a link between persin’s known effects on sphingolipid
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Figure 5. Inhibition of caspase-4 reduces persin-induced apoptosis. (A) MCF-7 and T-47D cells were treated with an apoptotic concentration of
persin (10 mgml 1) alone or in combination with caspase-4 inhibitor (20mM) or pan-caspase inhibitor (20mM) for 24 h, and then attached and
floating populations were analysed for M30-FITC positivity by flow cytometry. Representative histograms showing the M30-FITC-positive
(apoptotic) fraction are shown. (B) Bars, mean of M30-positive fractions from three independent experiments±s.e. ***Po0.001; ****Po0.0001 for
combination treatment vs single treatment.
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metabolism (Roberts et al, 2007) and its induction of ERS-
mediated apoptosis.
Previous work has linked key components of the ERS pathway
to the endocrine response. For example, Gu et al (2002) reported
that the development of anti-oestrogen resistance in vitro is
associated with an increase in XBP-1 expression in human breast
cancer cells, later demonstrating that XBP-1 is a key factor in
mediating anti-oestrogen responsiveness through modulating
apoptosis (Gomez et al, 2007). Clinical studies have also
demonstrated an association between XBP-1 activation and clinical
outcome in endocrine-treated breast cancers (Davies et al, 2008).
More recent studies have shown modulations in CHOP (Tiwary
et al, 2011) and BiP (Bru¨ning et al, 2010) associated with the
response to tamoxifen in vitro, including a reversal of tamoxifen
resistance (Tiwary et al, 2011). Furthermore, Ariazi et al (2011)
reported a CASP-4-dependent, ERS response was associated with
oestrogen-induced apoptosis in in vitro models of acquired
resistance.
However, despite these reports, the exact mechanisms involved
remain unclear—including what might shift the tamoxifen-induced
UPR from a survival to an apoptotic end point, and why
tamoxifen-resistant cells appear particularly sensitive to ERS
inducers. One possibility is that any further stress induction on
the heightened state of ERS present in a high proportion of breast
cancers (Fernandez et al, 2000; Scriven et al, 2009) tips the
survival/apoptosis balance causing cytotoxicity. In addition, given
that oestrogen stimulation can itself induce an UPR, the agonistic
response to tamoxifen displayed by some tamoxifen-resistant cells
may also contribute to increased ERS signalling and apoptosis.
Collectively, these studies and our recent data presented here
provide a strong rationale for further exploring the role of ERS
pathways in tamoxifen responsiveness in breast cancer, both as
potential biomarkers of the endocrine response and as novel
therapeutic targets to maximise responsiveness—particularly in
endocrine refractory disease. Furthermore, the accumulating data
on the overexpression of ERS signalling components, such as BiP
and XBP-1, in a high proportion of breast cancers (Scriven et al,
2009) and their effects on therapeutic resistance and clinical
outcomes (Lee et al, 2006; Davies et al, 2008; Tiwary et al, 2011),
emphasise their clinical relevance in this regard. Thus, the further
exploration of the mechanisms of action of persin or similar, more
therapeutically amenable analogues (Brooke et al, 2011) may have
clinical utility in this context.
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